Innovating Works

BBS

Desconocido
iAds: Intelligent design of adenovirus vectors (iAds) BATAVIA BIOSCIENCES BV participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist. Efficient gene...
2022-12-20 - 2027-04-30 | Financiado
ReCHISVac: Experimental vaccinology revealing unnatural signatures of protection by repeat controlled human sc... Schistosomiasis is a neglected tropical disease afflicting over 200 million people and causing 300,000 deaths in Africa alone. Whilst infect...
2022-05-10 - 2024-11-30 | Financiado
CardioReGenix: CardioReGenix Development of Next Generation Gene Therapies for Cardiovascular Disease BATAVIA BIOSCIENCES BV participó en un H2020: H2020-SC1-BHC-2018-2020 WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress...
2018-11-21 - 2024-06-30 | Financiado
RECOMB: Stem cell based gene therapy for recombination deficient SCID RECOMB BATAVIA BIOSCIENCES BV participó en un H2020: H2020-SC1-2016-2017 Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SC...
2017-11-21 - 2024-12-31 | Financiado
AD-VEC: Adenovirus Vector Technology Next Generation Systems for Medical Therapy BATAVIA BIOSCIENCES BV participó en un FP7: We propose a programme (AD-VEC) involving two industrial and three academic partners with the aim to identify new adenoviral vectors as vehi...
Financiado
ADVANCE: ADenoViruses as novel clinical treatments BATAVIA BIOSCIENCES BV participó en un FP7: ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to tra...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.